TABLE 2

Ongoing clinical studies investigating inhaled corticosteroid treatment for coronavirus disease 2019 (COVID-19) in adults

Trial no.	Name	Treatment	Setting	Primary outcome	n (planned)	Start date	Estimated or actual primary completion date	Location
JPRN-jRCTs031190269 [83]	RACCO	Ciclesonide 400 µg three times daily for 7 days	Hospital	Incidence of pneumonia on day 8 following treatment	90	April 2020	October 2020	Japan
NCT04381364 [84]	HALT COVID-19	Ciclesonide 320 µg twice daily for 14 days versus standard care	Hospital	Duration (days) of received supplemental oxygen therapy within 30 days after study inclusion	446	May 2020	August 2021	Sweden
EudraCT 2020-002208-37 [80]	CIMMCov	Ciclesonide 320 µg twice daily for 28 days versus placebo	Primary care	Reduction in healthcare resource utilisation (renewed contact with GP, emergency department and/or admission to hospital) due to COVID-19-related symptoms	138	June 2020^#	Ongoing^¶	Denmark
CTRI/2020/10/028581 [78]		Budesonide Rotacaps 200 µg twice daily for 10–14 days in addition to standard care versus standard care alone	Primary care	Hospitalisation	1000	October 2020	December 2020	India
CTRI/2021/05/033817 [79]		Budesonide 400 µg (two puffs twice daily) for up to 28 days versus standard care alone	Primary care	Hospitalisation or emergency department attendance related to COVID-19	820	May 2021⁺	Unknown	India
NCT04937543 [81]	TRIVID	Beclomethasone 250 µg or beclomethasone/formoterol/glycopyrronium 100/6/12.5 µg (two doses twice daily) for 28 days in addition to standard care versus standard care alone	Primary care	Use of healthcare resources 28 days after treatment	260	June 2021	October 2021	Brazil
NCT05054322 [82]	FLOT	Fluticasone propionate 125 µg with spacer (four puffs twice daily) for 14 days in addition to standard care	Primary care	Incidence of adverse outcomes (oxygen therapy, systemic corticosteroids, hospitalisation, mechanical ventilation and mortality) in symptomatic patients at 28 days after study inclusion	500	September 2021	January 2022	Vietnam

^#: Trial ongoing as of 11 January 2022 (date accessed). ^¶: Date on which this record was first entered in the EudraCT database. ⁺: Date of first enrolment (India). GP: general practitioner.